Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of YKYY013 in HBeAg-negative chronic hepatitis B infection on stable nucleos(t)ide analogue therapy
CTR20264005Phase 2Active
- Sponsor
- Yuekang Kechuang
- Start
- Nov 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of YKYY013 in hepatitis B (HBV), sponsored by Yuekang Kechuang. Started Nov 2026; status: active.
02
Drugs
YKYY013
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on CTR20264005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264005.